Search

Displaying results 2261 - 2270 of 4646 in total
  1. Drug

    Foslevodopa

    go.drugbank.com/drugs/DB16683
    Approved

    Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants With Advanced Parkinson's Disea...

    Synonyms: 3-hydroxy-O-phosphono-L-tyrosineMixtures: Produodopa 240 mg/ml + 12 mg/ml Infusionslösung
  2. Drug

    Nirmatrelvir

    go.drugbank.com/drugs/DB16691
    ApprovedInvestigational

    [L39544] It was fully approved by the FDA on May 25, 2023. … [A234224] Without the activity of the SARS-CoV-2 3CL<sup>PRO</sup>, nonstructural proteins (including proteases) cannot be released to perform their functions, inhibiting viral replication.

  3. Drug

    IDM-1

    go.drugbank.com/drugs/DB05292
    Experimental

    It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.

  4. Drug

    Amcipatricin

    go.drugbank.com/drugs/DB12333
    Investigational

    SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone

  5. Drug

    Botulinum toxin type A

    go.drugbank.com/drugs/DB00083
    ApprovedInvestigational

    In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use.

  6. Drug

    Foscarbidopa

    go.drugbank.com/drugs/DB16171
    Approved

    Foscarbidopa is under investigation in clinical trial NCT04379050 (Extension Study to Evaluate Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants With Parkinson's Disea...

    Mixtures: Produodopa 240 mg/ml + 12 mg/ml Infusionslösung
  7. Drug

    Plazomicin

    go.drugbank.com/drugs/DB12615
    Approved

    Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from DB12604. The structure of plazomicin was established via appending hydroxylaminobutyric acid to DB12604 at position 1 and...

  8. Drug

    Grazoprevir

    go.drugbank.com/drugs/DB11575
    Approved

    It can be used in patients with compensated cirrhosis, human immunodeficiency virus co-infection, or severe kidney disease. … HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852].

    Mixtures: ZEPATIER 50 MG/100 MG FİLM KAPLI TABLET, 28 ADET
  9. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized

  10. Drug

    Rozibafusp Alfa

    go.drugbank.com/drugs/DB19233
    Investigational

    Rozibafusp Alfa is under investigation in clinical trial NCT04058028 (Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)).